Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Open accessThe DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index; 17 of the 177 sources its claims cite were checked for support.
Abstract
Purpose of Review As a chronic and relapsing disease, obesity impairs metabolism and causes cardiovascular diseases. Although behavioral modification is important for the treatment of obesity, it is difficult to achieve an ideal weight or sustain the process of long-term weight loss. Therefore, the obesity control guidelines strongly recommend lifestyle interventions along with medical treatment for patients who are overweight. There is sufficient evidence supporting that pharmacotherapy in combination with behavior-based interventions can result in significant weight loss and improved cardiometabolism. Recent Findings Recent meta-analyses of new anti-obesity drugs and their weight-loss efficacy have shown that the overall placebo-subtracted weight reduction (%) for at least 12 months ranged from 2.9 to 6.8% for the following drugs: phentermine/topiramate (6.8%), liraglutide (5.4%), naltrexone/bupropion (4.0%), orlistat (2.9%), and lorcaserin (3.1%). However, very recently, on February 13, 2020, the US Food and Drug Administration (FDA) ordered the withdrawal of lorcaserin from markets, as a clinical trial to assess drug safety showed an increased risk of cancer. Currently, the anti-obesity medications that have been approved by the FDA for chronic weight management are orlistat, phentermine/topiramate, naltrexone/bupropion, and liraglutide. However, they are costly and may have adverse effects in some individuals. Therefore, drug therapy should be initiated in obese individuals after weighing its benefits and risks. Summary One of the strategies for long-term obesity control is that anti-obesity medications should be tailored for specific patients depending on their chronic conditions, comorbidities, and preferences.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 5 Not valid · 125 Not checked · 25 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The SCALE Diabetes assigned diabetic patients with obesity (n = 846) to receive 3 mg, 1.8 mg QD of liraglutide, or placebo for 56 weeks and reported weight reduction in the patients (6.0%, 4.7%, and 2.0%, respectively) [49].”
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Introduction > Currently Approved Anti-Obesity Drugs for Long-Term Use
What the sources say
- Disputedcites [49] Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. sourceExperimental — accuracy not yet measured
The Methods (p. 1) describe a different 56-week trial: 3,731 participants without type 2 diabetes received 3.0 mg liraglutide or placebo, with no 1.8 mg arm. Body Weight (p. 4) reports mean weight losses of 8.0% and 2.6%, not the three percentages attributed to this paper. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
plainstates a causen = 846- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In contrast, a previously conducted large cohort study (n = 33,625 with orlistat; 160,374 with placebo) showed no risk of colorectal cancer after the administration of orlistat [28].”
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Introduction > Currently Approved Anti-Obesity Drugs for Long-Term Use
What the sources say
- Partly supportedcites [28] Hong JL, Meier CR, Sandler RS, Jick SS, Stürmer T. Risk of colorectal cancer after initiation of orlistat: matched cohort study. BMJ. 2013;347:f5039. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, no difference was observed between both the groups in the incidence of depression, suicidal ideation, or hypoglycemia,”
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Introduction > Currently Approved Anti-Obesity Drugs for Long-Term Use
What the sources say
- Partly supportedcites [46] Jeon WS, Park CY. Antiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term management. Endocrinol Metab (Seoul). 2014;29:410–7. sourceExperimental — accuracy not yet measured
The naltrexone/bupropion section reports that hypoglycemia incidence did not differ between the COR-Diabetes treatment and placebo groups. It does not report a between-group comparison for depression or suicidal ideation; instead, it notes a boxed warning about suicidal thoughts and behaviors associated with bupropion. (LLM, conf=0.88)
plainn = 505- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In a recent study, the occurrence of adverse cardiovascular events among the users of phentermine/topiramate ER was less frequent than the unexposed former users [40].”
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Introduction > Currently Approved Anti-Obesity Drugs for Long-Term Use
What the sources say
- Supportedcites [40] Ritchey ME, Harding A, Hunter S, Peterson C, Sager PT, Kowey PR, et al. Cardiovascular safety during and after use of phentermine and topiramate. J Clin Endocrinol Metab. 2019;104:513–22. source
The Abstract Results report lower major adverse cardiovascular event (MACE) rates among current fixed-dose phentermine/topiramate users than among unexposed former users. The Results table likewise shows 0.39 versus 2.00 events per 1,000 person-years. The paper cautions that the confidence intervals were broad, but the citing sentence claims only that events were less frequent. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Energy intake decreased in the GLP-1 administration group, but energy intake increased more in the GIP+GLP-1 combination administration group (P = 0.039) [68].”
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Introduction > Gastric Inhibitory Polypeptide and GLP-1
What the sources say
- Supportedcites [68] Bergmann NC, Lund A, Gasbjerg LS, Meessen ECE, Andersen MM, Bergmann S, et al. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia. 2019;62(4):665–75. source
The Energy intake results (page not available) report lower energy intake with GLP-1 than with saline (p = 0.014). They also report higher intake with GIP+GLP-1 than with GLP-1 alone (p = 0.039), matching the cited comparison. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
65 more claims · 5 with their cited sources checked
Create a free account to see all 167 claims and to verify the 160 references still open.
- It may state two separate claims as one. 82
- Probably not a substantial claim. 33
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While sustainable weight loss is the primary goal of patients taking IBTs [2]”
From Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects (2025) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Introduction > Currently Approved Anti-Obesity Drugs for Long-Term Use
“it notably decreased the risk of T2DM in the drug-treated group”
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Introduction > Currently Approved Anti-Obesity Drugs for Long-Term Use
“(9.0%) as compared to the placebo-treated group (6.2%)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Introduction > Semaglutide
“first group was administered with final doses of 0.05, 0.1, 0.2, 0.3, and 0.4 mg of liraglutide (injected subcutaneously once daily)”
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Introduction > Semaglutide
“among the final semaglutide groups that were administered with final doses of 0.3 and 0.4 mg”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Introduction > Currently Approved Anti-Obesity Drugs for Long-Term Use
“has been approved by the EMA and the FDA since 1998 and 1999, respectively”
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Introduction > Currently Approved Anti-Obesity Drugs for Long-Term Use
“Yes 1999 | Yes 2012”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Abstract > Recent Findings
“the US Food and Drug Administration (FDA) ordered the withdrawal of lorcaserin from markets”
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Introduction > Lorcaserin
“the FDA officially issued a warning to the drug manufacturer to voluntarily withdraw lorcaserin from the market”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Introduction > GLP-1R/GCGR Agonists
“1.70 kg”
§ Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? > Introduction > GLP-1R/GCGR Agonists
“(90% CI, − 4.55. − 3.12 kg)”
Citations
Cites
Roth, G. A., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32203-7 · Cited by 8,600
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
(2020) · PubMed · Cited by 2,642
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Cited by
Ng, M., Gakidou, E., Lo, J., Abate, Y. H., Abbafati, C., Abbas, N., Abbasian, M., Abd ElHafeez, S., Abdel-Rahman, W. M., Abd-Elsalam, S., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00355-1 · Cited by 1,151
“Various pharmacotherapies for obesity have been launched in the past; 93 however, uptake was slow 94 due to the risk of serious side-effects 95,96 and contraindications for conditions such as cardiovascular diseases, which are common among individuals with obesity.”
Ng, M., Dai, X., Cogen, R. M., Abdelmasseh, M., Abdollahi, A., Abdullahi, A., Aboagye, R. G., Abukhadijah, H. J., Adeyeoluwa, T. E., Afolabi, A. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01548-4 · Cited by 344
He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., Xu, L., Li, W., & Zhang, H. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0338 · Cited by 356
Suren Garg, S., Kushwaha, K., Dubey, R., & Gupta, J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110691 · Cited by 224
Himmerich, H., Lewis, Y. D., Conti, C. M., Mutwalli, H., Karwautz, A. F. K., Sjögren, J. M., Uribe-Isaza, M. M., Tyszkiewicz‐Nwafor, M., Aigner, M., McElroy, S. L., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2023.2179663 · Cited by 153
Metadata
- Authors
- Tak, Y. J., & Lee, S. Y.
- Affiliations
- Pusan National University Hospital (KR)
- Pusan National University Yangsan Hospital (KR)
- Corresponding author
- Lee, Sang Yeoup
- Venue
- Current Obesity Reports
- Published
- 2021-01-06
- Volume
- 10
- Issue
- 1
- Pages
- 14-30
- ISSN
- 2162-4968 (ISSN-L)
- PMC
- PMC7787121
- OpenAlex
- W3118501255
- Semantic Scholar
- 5da3db28d45b3e26cd30db586df2c7c1f2fe739d
- Cited by
- 343
- References
- 116
- Citations by year
- 2026: 36 · 2025: 67 · 2024: 69 · 2023: 72 · 2022: 56 · 2021: 42
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Current Obesity Reports (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- anti-obesity drugs, obesity pharmacotherapy, long-term weight loss, phentermine/topiramate, liraglutide, naltrexone/bupropion, orlistat, lorcaserin, drug withdrawal, cancer risk, cardiometabolic risk, lifestyle intervention, personalized treatment, drug safety
- MeSH terms
- Liraglutide, Topiramate, Orlistat, Animals, Benzazepines, Humans, Naltrexone, Obesity, Phentermine, United States, United States Food and Drug Administration, Weight Loss, Bupropion, Anti-Obesity Agents, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? https://app.cochat.ai/papers/10.1007/s13679-020-00422-w
- The paper
- Tak, Y. J., & Lee, S. Y. (2021). Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Current Obesity Reports. https://doi.org/10.1007/s13679-020-00422-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.